← 返回

在空间和多路分辨率下剖析乳腺癌的肿瘤免疫微环境

英文原题:Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution.

查看英文原题

Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution.

PubMed 2022/04/14(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肿瘤免疫微环境(TIME)在乳腺癌病理生理学中发挥重要作用。抗肿瘤免疫应答的替代指标已被探索作为免疫治疗的预测性生物标志物,但存在若干局限性。程序性死亡配体1的免疫组织化学检测存在分析问题,免疫特征缺乏空间信息,TIL(肿瘤浸润淋巴细胞)的组织病理学评估存在观察者间变异。为更好地理解TIME中复杂的相互作用,若干新兴的多重原位方法正在开发中,并在蛋白质检测方面受到广泛关注。这些方法能够同时原位评估多个靶点,检测细胞密度/亚群,以及评估免疫浸润的功能状态。

此外,它们可以通过细胞间相互作用分析来表征TIME的空间组织,并评估不同感兴趣区域和组织隔室内的分布,同时数字成像和图像分析软件使各种检测方法具有可重复性。在本综述中,我们旨在概述癌症研究中使用的不同多重原位方法,特别关注新辅助、辅助和转移性乳腺癌TIME。

同时讨论TIME的空间异质性以及在治疗压力和转移进展下纵向评估TIME变化的重要性。

展开英文摘要原文

The tumor immune microenvironment (TIME) is an important player in breast cancer pathophysiology. Surrogates for antitumor immune response have been explored as predictive biomarkers to immunotherapy, though with several limitations. Immunohistochemistry for programmed death ligand 1 suffers from analytical problems, immune signatures are devoid of spatial information and histopathological evaluation of tumor infiltrating lymphocytes exhibits interobserver variability.

Towards improved understanding of the complex interactions in TIME, several emerging multiplex in situ methods are being developed and gaining much attention for protein detection. They enable the simultaneous evaluation of multiple targets in situ, detection of cell densities/subpopulations as well as estimations of functional states of immune infiltrate.

Furthermore, they can characterize spatial organization of TIME-by cell-to-cell interaction analyses and the evaluation of distribution within different regions of interest and tissue compartments-while digital imaging and image analysis software allow for reproducibility of the various assays.

In this review, we aim to provide an overview of the different multiplex in situ methods used in cancer research with special focus on breast cancer TIME at the neoadjuvant, adjuvant and metastatic setting. Spatial heterogeneity of TIME and importance of longitudinal evaluation of TIME changes under the pressure of therapy and metastatic progression are also addressed.

论文信息

作者
Tzoras E、Zerdes I、Tsiknakis N、Manikis GC、Mezheyeuski A、Bergh J、Matikas A、Foukakis T
单位
Department of Oncology-Pathology, Karolinska Institutet, 171 77 Stockholm, Sweden.Sweden
文献类型
综述
期刊
Cancers2022 Apr 14
原文标识
PubMed 35454904 · DOI 10.3390/cancers14081999